Claims for Patent: 7,423,050

Summary for Patent: 7,423,050

Title:	Pyridinoylpiperidines as 5-HT1F agonists
Abstract:	The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.
Inventor(s):	Michael Philip Cohen, Daniel Timothy Kohlman, Sidney Xi Liang, Vincent Mancuso, Yao-Chang Xu, Bai-Ping Ying, DeAnna Piatt Zacherl, Deyi Zhang, Frantz Victor
Assignee:	Eli Lilly and Co
Application Number:	US10/509,770
Patent Claims:	1. A compound of formula I: or a pharmaceutically acceptable acid addition salt thereof, where; R1 is phenyl substituted with one to three halo substituents; R2 is hydrogen or C1-C3 alkyl; R3 is hydrogen or methyl; R4 is hydrogen; and R5 is hydrogen. 2. The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benzamide or a pharmaceutically acceptable acid addition salt thereof. 3. The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benzamide hemisuccinate salt. 4. The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benzamide hydrochloride salt. 5. A pharmaceutical formulation comprising an effective amount of a compound of claim 1 and a pharmaceutical carrier, diluent, or excipient. 6. A pharmaceutical formulation comprising an effective amount of a compound of claim 2 and a pharmaceutical carrier, diluent, or excipient. 7. A pharmaceutical formulation comprising an effective amount of a compound of claim 3 and a pharmaceutical carrier, diluent, or excipient. 8. A pharmaceutical formulation comprising an effective amount of a compound of claim 4 and a pharmaceutical carrier, diluent, or excipient. 9. A method for the treatment of migraine in a mammal in need thereof comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I: or a pharmaceutically acceptable acid addition salt thereof, where; R1 is phenyl, substituted with one to three halo substituents; R2 is hydrogen or C1-C3 alkyl; R3 is hydrogen or methyl; R4 is hydrogen; and R5 is hydrogen. 10. The method according to claim 9 wherein the mammal is a human.